European Union - Bulgarian - EMA (European Medicines Agency)

ucb pharma s.a.   - ротиготин - restless legs syndrome; parkinson disease - Антипаркинсонови лекарства - leganto е показан за симптоматично лечение на умерен до тежък идиопатичен синдром на неспокойните крака при възрастни. leganto е показан за лечение на признаци и симптоми на болестта в ранен етап на идиопатична болест на Паркинсон като монотерапии (аз. без леводопа) или в комбинация с леводопа, т.е.. в рамките на болестта в по-късните стадии, когато ефектът на леводопа се износва или става непостоянен и колебания на терапевтичен ефект се случва (в края на дозата или "on-off' колебания).

Bulgaria - Bulgarian - Изпълнителна агенция по лекарствата

novo nordisk a/s - Глюкагон - l mg powder and solvent for injection

Bulgaria - Bulgarian - Изпълнителна агенция по лекарствата

novo nordisk a/s - Естрадиол, Норэтистерона ацетат - film - coated tablets

Bulgaria - Bulgarian - Изпълнителна агенция по лекарствата

novo nordisk a/s - Естрадиол, Норэтистерона ацетат -   1 mg/0,5 mg film - coated tablets

Bulgaria - Bulgarian - Изпълнителна агенция по лекарствата

novo nordisk a/s - Естрадиол - 2 mg film - coated tablets

Bulgaria - Bulgarian - Изпълнителна агенция по лекарствата

novo nordisk a/s - Соматропин - 5 mg/1,5 ml, solution for injection in catridge

European Union - Bulgarian - EMA (European Medicines Agency)

takeda pharma a/s - azilsartan medoxomil - Хипертония - Агенти, действащи върху системата ренин-ангиотензин - ipreziv е показан за лечение на есенциална хипертония при възрастни.

European Union - Bulgarian - EMA (European Medicines Agency)

alexion europe sas - себелапаза алфа - Липиден метаболизъм, вродени грешки - Други стомашно-чревния тракт и обмяната на веществата средства, - kanuma е показан за дългосрочна ензимна заместителна терапия (ert) при пациенти на всички възрасти с дефицит на лизозомална киселина липаза (lal).

European Union - Bulgarian - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - Хемоглобинурия, пароксизма - Селективни имуносупресори - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

European Union - Bulgarian - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - Неоплазми на гърдата - Антинеопластични средства - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.